A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 6, 2008, Pages 953-963

  Meng, Fanying ^a   Cai, Xiaohong ^a   Duan, Jianxin ^a   Matteucci, Mark G ^a   Hart, Charles P ^a  

^a Threshold Pharmaceuticals   (United States)

Author keywords

Cell cycle; Cytotoxicity; Drug resistance; In vitro vessel disrupting activity; Microtubules; Tubulin; Tubulin inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; DNA TOPOISOMERASE INHIBITOR; INDAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BRCP1; STIROCAINIDE; TH 337; TH 482; TUBULIN INHIBITOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG POTENCY; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROTUBULE ASSEMBLY; PANCREAS CARCINOMA; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ATP-BINDING CASSETTE TRANSPORTERS; CALORIMETRY, DIFFERENTIAL SCANNING; CAPILLARY PERMEABILITY; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEINS; FLUORESCENT DYES; G2 PHASE; HUMANS; MICROSCOPY, FLUORESCENCE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; TUBULIN; TUBULIN MODULATORS;

EID: 41049093659     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0549-x     Document Type: Article

References (44)

1. Hadfield JA, Ducki S, Hirst N et al (2003) Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 5:309-325
2. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265
3. Yoshida D, Hoshino S, Shimura T et al (2000) Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study. J Neurooncol 47:133-140
4. Mayer TU, Kapoor TM, Haggarty SJ et al (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971-974
5. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435
6. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685-693
7. Chang YS, di Tomaso E, McDonald DM et al (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97:14608-14613
8. Lippert JW (2007) Vascular disrupting agents. Bioorg Med Chem 15:605-615
9. Nicholson B, Lloyd GK, Miller BR et al (2006) NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 17:25-31
10. Peifer C, Stoiber T, Unger E et al (2006) Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem 49:1271-1281
11. Davis PD, Dougherty GJ, Blakey DC et al (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253
12. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
13. Szakacs G, Annereau JP, Lababidi S et al (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129-137
14. Szakacs G, Paterson JK, Ludwig JA et al (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234
15. Lee JS, Paull K, Alvarez M et al (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46:627-638
16. Shoemaker RH (2000) Genetic and epigenetic factors in anticancer drug resistance. J Natl Cancer Inst 92:4-5
17. Goncalves A, Braguer D, Kamath K et al (2001) Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 98:11737-11742
18. Giannakakou P, Sackett DL, Kang YK et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118-17125
19. Zhang CC, Yang JM, White E et al (1998) The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16:1617-1624
20. Kavallaris M, Kuo DY, Burkhart CA et al (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100:1282-1293
21. Duan JX, Cai X, Meng F et al (2007) Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles. J Med Chem 50:1001-1006
22. Robey RW, Honjo Y, Morisaki K et al (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978
23. Meng F, Nguyen XT, Cai X et al (2007) ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1 alpha accumulation. Anticancer Drugs 18:435-445
24. Bonne D, Heusele C, Simon C et al (1985) 4′,6-Diamidino-2- phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem 260:2819-2825
25. Cushman M, Nagarathnam D, Gopal D et al (1992) Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem 35:2293-2306
26. Harker WG, Sikic BI (1985) Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45:4091-4096
27. Hipfner DR, Gauldie SD, Deeley RG et al (1994) Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792
28. Harker WG, Slade DL, Drake FH et al (1991) Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30:9953-9961
29. Ruben AJ, Kiso Y, Freire E (2006) Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem Biol Drug Des 67:2-4
30. Franklin TJ, Jacobs V, Jones G et al (1996) Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res 56:984-987
31. Lichtner RB, Rotgeri A, Bunte T et al (2001) Subcellular distribution of epothilones in human tumor cells. Proc Natl Acad Sci USA 98:11743-11748
32. Jordan MA, Wendell K, Gardiner S et al (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825
33. Gwaltney SL 2nd, Imade HM, Barr KJ et al (2001) Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg Med Chem Lett 11:871-874
34. Romagnoli R, Baraldi PG, Remusat V et al (2006) Synthesis and biological evaluation of 2-(3′,4′,5′-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors. J Med Chem 49:6425-6428
35. Romagnoli R, Baraldi PG, Pavani MG et al (2006) Synthesis and biological evaluation of 2-amino-3-(3′,4′,5′-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents. J Med Chem 49:3906-3915
36. Shan B, Medina JC, Santha E et al (1999) Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 96:5686-5691
37. Tron GC, Pirali T, Sorba G et al (2006) Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 49:3033-3044
38. Helmlinger G, Netti PA, Lichtenbeld HC et al (1997) Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol 15:778-783
39. Tozer GM, Prise VE, Wilson J et al (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634
40. Baguley BC, Holdaway KM, Thomsen LL et al (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482-487
41. Hill SA, Lonergan SJ, Denekamp J et al (1993) Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29A:1320-1324
42. Tozer GM, Prise VE, Wilson J et al (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61:6413-6422
43. Gifford SM, Grummer MA, Pierre SA et al (2004) Functional characterization of HUVEC-CS: Ca2+ signaling, ERK 1/2 activation, mitogenesis and vasodilator production. J Endocrinol 182:485-499
44. Vincent L, Kermani P, Young LM et al (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006